Sandbox bcce8

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
==β-Glucuronidase==
==β-Glucuronidase==
<StructureSection load='3hn3' size='340' side='right' caption='Caption for this structure' scene=''>
<StructureSection load='3hn3' size='340' side='right' caption='Caption for this structure' scene=''>
-
This tutorial illustrates the quaternary structures of the human and E. coli &beta-glucuronidase enzyme.
+
This tutorial illustrates the quaternary structures of the human and E. coli &beta;-glucuronidase enzyme.
== Function ==
== Function ==
-
&beta-glucuronidase is a ubiquitous enzyme that catalyzes the hydrolysis of a glucuronide moiety from a variety of substrates. This enzyme is present throughout biological systems, including bacteria up through humans.
+
&beta;-glucuronidase is a ubiquitous enzyme that catalyzes the hydrolysis of a glucuronide moiety from a variety of substrates. This enzyme is present throughout biological systems, including bacteria up through humans.
== Relevance ==
== Relevance ==
Deficiencies in the human form of &beta-glucuronidase is associated with a disease known as Sly Syndrome (AKA Mucopolysaccharidosis VII -- MPS VII). This disease is characterized by mental retardation, short stature, macrocephaly, and enlarged joints. As is commonly seen with genetic disorders, patients with this disease present a spectrum of symptom severity, but the disease is always ultimately fatal.
Deficiencies in the human form of &beta-glucuronidase is associated with a disease known as Sly Syndrome (AKA Mucopolysaccharidosis VII -- MPS VII). This disease is characterized by mental retardation, short stature, macrocephaly, and enlarged joints. As is commonly seen with genetic disorders, patients with this disease present a spectrum of symptom severity, but the disease is always ultimately fatal.
-
The E. coli form of &beta-glucuronidase is associated with the side effects seen with administration of the cancer chemotherapy drug CPT-11. This drug gets converted to SN38, a topoisomerase inhibitor, by the liver. The body adds a glucuronide group to this molecule (now SN38-G) to mark it for elimination, which partially occurs through the intestine. Once in the intestine, bacterial b-glucuronidase cleaves the glucuronide from the SN38-G, releasing the SN38 into the intestinal lumen. The released SN38 prevents cell division, compromising the epithelial lining of the intestines, a painful and dangerous side-effect of CPT-11 administration.
+
The E. coli form of &beta;-glucuronidase is associated with the side effects seen with administration of the cancer chemotherapy drug CPT-11. This drug gets converted to SN38, a topoisomerase inhibitor, by the liver. The body adds a glucuronide group to this molecule (now SN38-G) to mark it for elimination, which partially occurs through the intestine. Once in the intestine, bacterial &beta;-glucuronidase cleaves the glucuronide from the SN38-G, releasing the SN38 into the intestinal lumen. The released SN38 prevents cell division, compromising the epithelial lining of the intestines, a painful and dangerous side-effect of CPT-11 administration.
-
Selective inhibition of bacterial &beta-glucuronidase is desired to alleviate this side-effect of CPT-11 treatment, hopefully without inhibiting the human form of the enzyme.
+
Selective inhibition of bacterial &beta;-glucuronidase is desired to alleviate this side-effect of CPT-11 treatment, hopefully without inhibiting the human form of the enzyme.

Revision as of 14:39, 6 August 2014

β-Glucuronidase

Caption for this structure

Drag the structure with the mouse to rotate

References

Personal tools